Diagnostic Consultative Center 14 Sofia EOOD
- Address
- lock Available on a paid plan
Diagnostic Consultative Center 14 Sofia EOOD
Diagnostic Consultative Center 14 Sofia EOOD is a clinical research facility specializing in diverse therapeutic areas with a focus on neurological, psychiatric, and immunological disorders. The center demonstrates comprehensive expertise in conducting phase II and long-term safety studies, ranging from neurodegenerative conditions to chronic inflammatory diseases.
- Psychiatric disorders including schizophrenia with novel muscarinic receptor agonist therapies
- Neurodegenerative diseases, particularly agitation management in Alzheimer's-type dementia
- Dermatological conditions with emphasis on moderate-to-severe atopic dermatitis treatment
- Rheumatoid arthritis in DMARD-naïve patients with early disease manifestation
The center's research portfolio reflects significant experience in evaluating both long-term safety and efficacy outcomes across multiple disease states. Their work encompasses innovative therapeutic approaches, including biologics for dermatological conditions, novel compounds for psychiatric disorders, and combination therapies for autoimmune diseases, positioning them as a versatile research institution capable of managing complex clinical trial protocols in adult and adolescent populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Immunic AG2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Immunic AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic Consultative Center 14 Sofia EOOD
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vidofludimus Calcium | 3 | Unknown | 2019-01-23 | 2022-03-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.